填空题
{{B}}PART ONE{{/B}}
{{B}} · Look at the sentences below and
following texts.
· Which text does each sentence refer to?
·
For each sentence 1--8, mark one letter A, B, C, D or E.
· You will
need to use some of the letters more than once.{{/B}}
{{B}}A. Cablevision Extends $ 90 Triple-Service Promotion{{/B}}
Persuaded by
popular demand, Cablevision Systems Corp. (CVC) is extending a promotional offer
that combines cable TV, Internet and phone service for $ 90 a month. First
launched in mid-June, the offer was originally slated to end July 31 but was
pushed out to mid-August. Now it seems the company wants hold on to the offer
still longer. The Bethpage, N. Y., company hasn't specified when the promotion
will end. During a quarterly conference call last week, Chief Operating
Officer Tom Rutledge said simply that the company was continuing to advertise
the offer based on its early success. Rutledge also said promotional offers
"will continue to play a key role in both building new customer relationships
and expanding existing ones."
{{B}}B. McDonald' s CEO has new
surgery{{/B}}
The chief executive of McDonald's Corp. is recuperating after
another surgery, the world's largest fast-food company said Saturday. Charlie
Bell underwent a procedure Friday to correct a blockage caused by scar tissue
build-up from colorectal surgery he had in May, the company said. "I am
delighted to report that The procedure was a complete success and that Charlie
is resting comfortably," said Andrew McKenna, chairman of Chicago area-based
McDonald's. "During Charlie's brief recuperation period... there is absolutely
no change in the leadership of the company," McKenna said in a statement. Bell,
previously chief operating officer of the global fast-food giant, became CEO
after the unexpected death in April of former CEO Jim Cantalupo at a meeting in
Florida.
{{B}}C. Google governance flawed{{/B}}
Google Inc. ranks lower in
corporate governance than any company in the Standard Poor's 500 stock index,
according to influential proxy adviser Institutional Shareholder Services, said
a newspaper report published Monday. ISS, which advises shareholders on how to
vote, found 21 weaknesses in the governance practices of Mountain View, Calif.-
based Google, which is expected to join the S&P 500, said the Financial Times.
These flaws, it said, include a dual-class capital structure that gives
effective control to insiders, too few outside directors and a lack of stock
ownership guidelines for executives and independent directors. The adviser also
found problematic of the company's compensation plan that lets Google reprice
stock options if the stock price falls, as well as loans to company
insiders.
{{B}}D. US Airways talks with pilots collapse{{/B}}
Negotiations
between US Airways and its pilots union over a new round of steep concessions
collapsed on Monday, heightening pressure on the carrier as it tries to avert
insolvency. Jack Stephan, a spokesman for the company's chapter of the Air Line
Pilots Association, said more than a week of discussions between the two sides
at the airline's Arlington, Va. , headquarters yielded little progress. "Since
the beginning of these talks, we have witnessed a disturbing trend by the
company to seemingly dismiss several significant proposals from our pilot
negotiators," Stephan said. "Instead, management has responded by 'piling on'
additional demands to their counterproposals."
{{B}}E. Mylan wins OK for
generic Zoloft{{/B}}
Shares of Mylan Laboratories Inc. rose Monday after
U. S. regulators gave tentative marketing approval to the company's generic
forms of popular depression and allergy drugs sold by Pfizer Inc. Mylan said the
Food and Drug Administration had granted tentative approval to its forms of
Pfizer's Zoloft, or sertraline, anti-depressant, and Zyrtec, or cetirizine,
allergy pill. But Mylan will not be allowed to sell the copycats for several
years until Pfizer's patents on the medicines expire. Zoloft and Zyrtec are
among Pfizer's biggest products, with global 2003 sales of $ 3.12 billion for
Zoloft, and $1.34 billion, for Zyrtec.